Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0G6ZG
|
||||
Former ID |
DCL000691
|
||||
Drug Name |
Amediplase
|
||||
Synonyms |
Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Menarini
|
||||
Structure |
Download2D MOL |
||||
Formula |
C22H18O4
|
||||
Canonical SMILES |
C1=CC=C2C(=C1)C(C(C3=C2C=C4C=CC5=C(C4=C3)C=CC(C5O)O)O)O
|
||||
InChI |
1S/C22H18O4/c23-19-8-7-13-15(20(19)24)6-5-11-9-17-12-3-1-2-4-14(12)21(25)22(26)18(17)10-16(11)13/h1-10,19-26H/t19-,20-,21-,22-/m0/s1
|
||||
InChIKey |
YQINXCSNGCDFCQ-CMOCDZPBSA-N
|
||||
CAS Number |
CAS 151912-11-7
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
B01AC07
|
||||
SuperDrug CAS ID |
cas=000058322
|
||||
Target and Pathway | |||||
Target(s) | Urokinase-type plasminogen activator | Target Info | Activator | [536186] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
EGFR1 Signaling Pathway | |||||
Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
E2F transcription factor network | |||||
Beta3 integrin cell surface interactions | |||||
Osteopontin-mediated events | |||||
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
amb2 Integrin signaling | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
Beta2 integrin cell surface interactions | |||||
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
FGF signaling pathway | |||||
Reactome | Dissolution of Fibrin Clot | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.